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Aim The optimal duration of dual antiplatelet therapy (DAPT) following the use of new generation drug-eluting stents is
unknown.
Methods
and results
The association between DAPT interruption and the rates of stent thrombosis (ST) and cardiac death/target-vessel myo-
cardial infarction (CD/TVMI) in patients receiving a Resolute zotarolimus-eluting stent (R-ZES) was analysed in 4896
patients from the pooled RESOLUTE clinical programme. Daily acetylsalicylate (ASA) and a thienopyridine for 6–12
months were prescribed. A DAPT interruption was defined as any interruption of ASA and/or a thienopyridine of
.1 day; long interruptions were .14 days. Three groups were analysed: no interruption, interruption during the first
month, and .1–12 months. There were 1069 (21.83%) patients with a DAPT interruption and 3827 patients with no
interruption. Among the 166 patients in the 1-month interruption group, 6 definite/probable ST events occurred
(3.61%; all long DAPT interruptions), and among the 903 patients in the .1–12 months (60% occurred between
6 and 12 months) interruption group, 1 ST event occurred (0.11%; 2-day DAPT interruption). Among patients with
no DAPT interruption, 32 ST events occurred (0.84%). Rates of CD/TVMI were 6.84% in the 1-month long interruption
group, 1.41% in the .1–12 months long interruption group, and 4.08% in patients on continuous DAPT.
Conclusion In a pooled population of patients receiving an R-ZES, DAPT interruptions within 1 month are associated with a high risk
of adverse outcomes. Dual antiplatelet therapy interruptions between 1 and 12 months were associated with low rates
of ST and adverse cardiac outcomes. Randomized clinical trials are needed to determine whether early temporary or
permanent interruption of DAPT is truly safe.
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Introduction
The introduction of drug-eluting stents (DES) for the treatment of
coronary artery disease has significantly reduced revascularization
rates following percutaneous coronary intervention. However, the
early enthusiasm for the first generation DES was tempered by
reports of an increased risk of late (30 days to 1 year) and very late
(beyond 1 year) stent thrombosis (ST) with these devices.1 –6
These concerns, based on retrospective observational data with
first generation sirolimus-eluting and paclitaxel-eluting stents,2,4 led
to multi-disciplinary society guideline recommendations for extended
durationofdual antiplatelet therapy (DAPT) inEurope (6–12months)
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and in the USA for at least 12 months DAPT following percutaneous
coronary revascularization with a DES.7–13 These recommendations
stemmed from historical observations that DAPT with a thienopyri-
dine and acetylsalicylic acid (ASA) can effectively reduce ST.14–16 Fur-
thermore, in several observational studies, early discontinuation of the
thienopyridine, clopidogrel, was identified as a strong predictor for
ST.17–19 However, the current clinical practice guidelines were
limited by the lack of randomized controlled data comparing the effi-
cacy and safety of 6 and 12 months of DAPT. More recently, three ran-
domized studies regarding the duration of DAPT have been published
but compare either 6 month vs. 1 or 2 year DAPT.20,21 or 1 year vs. 2
year DAPT.22 None showed superiority of the longer DAPT duration.
There remains limited evidence addressing the risks and benefits of
prolonged DAPT with newer generation DES that have demonstrated
a superior safety profile and lower overall rate of ST when compared
towith first generation DES.23–25 In fact, in light of recent safety data
with newer generation DES platforms, some have questioned whether
the risk of ST still represents a significant limitation to the use of DES.26
Given the paucity of randomized trial data to define optimal
duration of DAPT with new generation DES and the importance of
minimizing risks for adverse events following percutaneous revascu-
larization with DES, we undertook a detailed post hoc analysis to
assess the impact of DAPT interruption on ST following implantation
of the ResoluteTM zotarolimus-eluting stent (R-ZES, Medtronic, Inc.,
Santa Rosa, CA, USA). Because ST is a rare event but is associated
with serious clinical consequences,27 the analysis also includes an as-
sessment of cardiac death and target-vessel myocardial infarction
(CD/TVMI) for patients with and without a DAPT interruption as
well as additional details related to the DAPT interruption and ST.
Methods
Clinical data were pooled from four prospective multicentere clinical
trials of the R-ZES; RESOLUTE-All Comers (R-AC, n ¼ 1140),
RESOLUTE-International (R-INT, n ¼ 2349), RESOLUTE-Japan (R-J,
n ¼ 100), and RESOLUTE-US (R-US, n ¼ 1402). The RESOLUTE
First-in-Man (R-FIM) trial was not included because the required data
on DAPT use were not collected in this trial. Across the entire RESO-
LUTE global clinical programme consistent methodology was employed
to allow data from multiple trials to be pooled in order to provide more
reliable estimates of the true risk of clinical safety events. Specifically,
these clinical trials were conducted using similar data collection proce-
dures, identical adjudication processes, and consistent endpoint defini-
tions.28–31 Notably, the R-AC and R-INT trials included a large
number of patients with complex clinical or lesion characteristics. All
trials were 100% monitored with the exception of R-INT which was
25% monitored in the first year, and Clinical Event Committees were har-
monized across the trials to ensure consistency in adjudication and com-
parability of the data from the different trials. All trials complied with the
Declaration of Helsinki, were approved by the appropriate ethics commit-
tees for each site and informed consent was obtained from all patients.
All trials recommended ASA was to be given indefinitely and a thieno-
pyridine (clopidogrel 75 mg daily or ticlopidine 250 mg twice daily) for a
minimum of 6 months and optimally for 12 months. For the purposes of
this analysis, patients must have had key DAPT data available including
start and stop dates of the thienopyridine or ASA. Additionally, 34
patients who started DAPT more than a day after stent implantation
were excluded from this analysis (including a single patient who had a
ST event prior to the start of DAPT) (Figure 1).
A DAPT interruption was defined as either a temporary interruption
of ASA and/or a thienopyridine (interruption of.1 day), or a permanent
discontinuation. Based on reports that the pharmacodynamics effects of
thienopyridines on platelet aggregation can take up to 14 days to clear
following DAPT interruption,32 patients with a DAPT interruption of
longer than 14 days were also analysed. Reasons for DAPT interruptions
were categorized as clinical, procedural, or patient non-adherence based
on reasons checked on patient case report forms. The timing of the
first interruption was used to classify patients into an interruption
group; patients in whom a ST occurred while on DAPT were included
in the non-interruption group even if there was a DAPT interruption
after the event.
Stent thrombosis events were categorized according to the Academic
Research Consortium (ARC) definitions.33 The impact of DAPT inter-
ruption within the first year after stent implantation on 1 year definite
and probable ST events was analysed by categorizing the timing of inter-
ruption into three groups: patients with no DAPT interruption, DAPT
interruption during the first month (30 days), and DAPT interruption
between 1 and 12 months (Figure 1). All the patients who had a DAPT
interruption within 12 months of the PCI procedure were followed for
a full year after the time of the DAPT interruption to fully assess risk
for ST. The population utilized for DAPT interruption analyses was
also used to assess the incidence of CD/TVMI based upon DAPT inter-
ruption status. Bleeding events, which were available for the subgroup
of patients enrolled on the R-INT trial, were analysed in a similar
fashion based upon DAPT interruption status.
Statistical methods
The three analysis groups were based on timing of DAPT interruption
(no interruption, interruption in the first month, and interruption after
1 to 12 months following stent placement) and were pre-specified
before the post hoc analysis was undertaken. Descriptive statistics for
the baseline characteristics are provided. Categorical variables were
reported as counts and percentages, and were assessed using Pearson’s
Chi-square test. Continuous variables were presented as means+ SD
and were compared using one-way analysis of variance. The Kaplan–
Meier method was used to calculate the cumulative incidence of ST
events, and the log-rank test was used to compare between-group differ-
ences.A two-sidedP-value of,0.05wasconsidered to indicate statistical
significance. Data analysis was conducted independently by the Harvard
Clinical Research Institute (Boston, MA, USA ).
Results
There were 1069 (21.8%) patients who had a DAPT interruption and
3827 patients who continued DAPT with no interruption. Among
patients with a DAPT interruption 166 (15.5%) interrupted in the
first month, another 92 (8.6%) interrupted between 1 and 3 months,
and 171 (16.0%) interrupted DAPT between 3 and 6 months
(Figure 2). Among patients with a classifiable reason for DAPT
interruption, temporary DAPT interruption was usually prior to a
medical/dental/surgical procedure (42.2%) or for another clinical
indication (12.8%), whereas permanently discontinued DAPT most
often occurred because patients completed their prescribed course
(46.0%) (Figure 3). Stent thrombosis events were evenly distributed
across the different reasons for DAPT interruption.
Baseline patient and lesion characteristics of the 4896 patients
included in the analysis are shown in Table 1. The incidence of dia-
betes (30%) and acute coronary syndromes (overall 40%) was
similar between the three groups; however, patients with a DAPT
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interruption in the first month were older and had lower left
ventricular ejection fractions. In addition, these patients had more
B2/C class lesions and smaller reference vessel diameter, but
shorter lesion lengths.
Timing of stent thrombosis
In total, 39 cases of ST occurred during the first year following R-ZES
implantation. Overall, 32 (82.1%) cases of ST occurred when patients
wereonDAPTand7 (17.9%)STeventsoccurredwhenpatientswere
Figure 2 Distribution of patients according to time of first dual antiplatelet interruption.
Figure 1 Patient disposition according to dual antiplatelet therapy interruption status. DAPT, dual antiplatelet therapy; R-AC, RESOLUTE-All
comers; R-INT, RESOLUTE-International; R-J, RESOLUTE-Japan; R-US, RESOLUTE-US.
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off DAPT at the time of ST (Figure 4). Among the 29 ST events occur-
ring early (within 30 days), 25 of these events occurred on DAPT and
4 occurred off DAPT. Among the 10 cases of late ST, 7 occurred on
DAPT and 3 occurred off DAPT.
Dual antiplatelet therapy interruption
Among the 3827 patients with no DAPT interruption, there were
32 ST events (0.84%). Among patients with DAPT interruption,
166 patients interrupted DAPT in the first month, with 6 ST events
occurring in this group (3.61%). Among 903 patients with a DAPT
interruption between 1 and 12 months, one ST event occurred
(0.11%). Kaplan–Meier estimates of the cumulative incidence of ST
events showed a significant difference between patients interrupted
in the first month and patients with a DAPT interruption between 1
and 12 months (log-rank P, 0.001; Figure 5). In addition to the ST as-
sessment at 12 months, when the 1069 patients with any DAPT
Figure 3 Reasons given for dual antiplatelet therapy interruptions.
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Table 1 Baseline demographic and lesion characteristics
Baseline characteristics Never
interrupted,
n5 3827 patients
Interrupted first
month, n 5 166
patients
Interrupted >1–12
months, n 5 903
patients
P-value
Age (years) 63.4+10.8 (3827) 66.6+12.0 (166) 65.5+11.3 (903) ,0.001
History of smoking 59.1% (2261/3827) 53.0% (88/166) 58.4% (527/903) 0.289
Prior percutaneous coronary revascularization 30.7% (1176/3827) 27.1% (45/166) 33.1% (299/903) 0.204
Diabetes mellitus 29.6% (1134/3827) 32.5% (54/166) 31.8% (287/903) 0.354
Insulin dependent 8.5% (327/3827) 10.8% (18/166) 10.2% (92/903) 0.201
Prior MI 25.6% (974/3800) 22.7% (37/163) 27.1% (242/893) 0.435
Left ventricular ejection fraction ,30% 1.8% (48/2630) 5.7% (6/105) 2.1% (14/671) 0.020
Lesion class B2/C 65.9% (3271/4960) 72.7% (152/209) 68.5% (791/1154) 0.040
ACS 42.4% (1621/3827) 42.2% (70/166) 40.0% (361/903) 0.427
STEMI 8.5% (327/3827) 8.4% (14/166) 6.9% (62/903) 0.255
NSTEMI 7.8% (297/3827) 7.8% (13/166) 8.3% (75/903) 0.861
Unstable angina 26.1% (997/3827) 25.9% (43/166) 24.8% (224/846) 0.744
Pre-procedure RVD (mm) 2.79+0.51 (4767) 2.70+0.56 (198) 2.76+0.53 (1092) 0.010
Lesion length (mm) 15.93+9.66 (4744) 14.77+8.33 (198) 15.09+8.95 (1091) 0.010
Number of stents per patient 1.56+0.94 (3827) 1.53+1.10 (166) 1.52+0.90 (903) 0.615
Total stent length per patient (mm) 29.38+19.56 (3826) 27.84+22.49 (166) 27.83+18.84 (903) 0.071
Stent diameter (mm) 2.95+0.45 (6367) 2.93+0.46 (271) 2.94+0.45 (1467) 0.476
Data are presented as means+ SD or % (n/N).
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interruption were followed for one full year after the time of DAPT
interruption, no additional ST events were identified beyond the
seven events described here.
Dual antiplatelet therapy interruption
longer than14 days
Among the 874 patients with a DAPT interruption longer than 14
days, 122 interrupted in the first month. All of the six ST events
that occurred in the firstmonth were in these patients who had a pro-
longed DAPT interruption. Among the 752 patients with a longer
than 14 day DAPT interruption between 1 and 12 months, there
was no ST event.
Thienopyridine interruption
In patients with a DAPT interruption, the thienopyridine alone was
interrupted in 662 (61.9%) patients; there were three total ST
events in this group. Among patients interrupting thienopyridine
only, 67 patients interrupted the thienopyridine within 1 month
[with two STevents (3.0%)], and 595 patients interrupted the thieno-
pyridine between 1 and 12 months [with one ST event (0.2%)].
Acetylsalicylate interruption
In patients with a DAPT interruption, the ASA alone was interrupted
in 196 (18.3%) patients; there were four total ST events in this group.
Among patients interrupting ASA only, 78 patients interrupted ASA
within 1 month [with four ST events (5.1%)], and 118 patients inter-
rupted ASA between 1 and 12 months (no ST events).
Simultaneous interruption
In patients with a DAPT interruption, simultaneous interruption of
both the thienopyridine and ASA therapies occurred in 211
(19.7%) patients. Among these patients, 21 interrupted DAPT
within the first month and 190 patients interrupted between 1 and
12 months. Notably, there were no ST events in either group.
Permanent discontinuation of dual
antiplatelet therapy
Among patients with a DAPT interruption, there were 695 patients
(65.0%) who stopped DAPT permanently; of these, 69 occurred
within the first month. All four ST events among patients with
permanent DAPT discontinuation occurred in patients who perma-
nently discontinued DAPT within the first month.
Figure 4 Timing of stent thrombosis regardless of time of dual
antiplatelet therapy interruption. DAPT, dual antiplatelet therapy;
ST, stent thrombosis.
Figure 5 Cumulative incidence of definite or probable stent thrombosis through 1 year after stent implantation according to dual antiplatelet
therapy interruption status. ST, stent thrombosis.
Lack of association between dual antiplatelet therapy use and stent thrombosis 1953
Details of stent thrombosis events in dual
antiplatelet therapy interrupted patients
Of the seven ST events that occurred in DAPT interrupted patients
within 1 year after the interruption, threeweredefinite and four were
probable (Table 2). Two definite ST and four probable ST events
were in patients who had a DAPT interruption within the first
month. The median number of days to interruption following the
PCI for all six patients in this group was 2 days.
For the single case of ARC definite ST that occurred in the inter-
rupted group between 1 and 12 months, the patient had a history
of ST prior to the PCI procedure and had two total occlusions
close to the previously implanted stents that were treated during
the PCI procedure (Table 2). The median number of days to interrup-
tion for all patients was 211 days.
Cardiac death/target-vessel myocardial
infarction by dual antiplatelet therapy
interruption longer than 14 days
Overall there were 4071 patients who never interrupted DAPT.14
days or were on DAPT at the time of the CD or TVMI. Among
patients who never interrupted DAPT longer than 14 days, the rate
of CD/TVMI was 4.08% (166/4071). The rate of CD/TVMI was
6.84% in patients with a longer than 14 day DAPT interruption
within the first month; lower rates of CD/TVMI occurred in patients
interrupted longer than14days between 1–3, 3–6and6–12months
(Figure 6).
Bleeding outcomes
Of the 2309 patients from R-INT with bleeding data ascertained,
1896 patients had no DAPT interruption prior to any bleeding
event; there were 34 bleeding events in these patients (1.79%). No
patient who had a DAPT interruption within the first month (n ¼
56) had a bleeding event, and two bleeding events occurred in the
357 patients (0.56%) with a DAPT interruption from 1 to 12 months.
Discussion
In patientswith stablecoronaryarterydisease, current recommenda-
tions for DES call for a minimum of 6 months in the European7,8 and
12 months in the US guidelines.9 The recently revised American
College of Cardiology Foundation/American Heart Association
guidelines for management of ST-elevation myocardial infarction re-
commend 12 months DAPT duration and a strict minimum of 6
months following DES placement for these high-risk patients.10 In
patients with acute coronary syndromes, both guidelines recom-
mend DAPT for 12 months, irrespective of stent type.7– 9,11– 13
However, prolonged DAPT has been associated with higher bleeding
rates,34 and optimal DAPT duration with new generation DES is
unknown. In this analysis, .4800 patients treated with the R-ZES,
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Table 2 Details of stent thrombosis events in patients with dual antiplatelet therapy interruption within 1 year of PCI
procedure
Patient Time of
interruption
Duration of
interruption
Interrupted
medication
Timeof STevent (duration
of interruption until ST)
ARCclassification
of ST event
DAPT interruption 0–1 month
1 Day 1 Permanenta ASA Day 108 (108) Probable
2 Day 1 Permanentb ASA Day 2 (2) Probable
3 Day 3 33 days ASA Day 22 (20) Definite
4 Day 2 Permanentb Clopidogrel Day 4 (3) Probable
5 Day 2 Permanent ASA Day 5 (4) Probable
6 Day 2 30 days Clopidogrel Day 32 (31) Definite
DAPT interruption 1–12 months
7 Day 69 2 Clopidogrel Day 71(3) Definite
aPatient was permanently off DAPT for 108 days before ST event and death.
bPatients died after ST event within 2–3 days of DAPT interruption.
Figure 6 Distribution of patients with cardiac death or target-
vessel myocardial infarction per interval of dual antiplatelet inter-
ruption longer than 14 days. The mean value for the grouped inter-
ruption interval of 1 to ,12 months was 1.41%.
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we found that most ST events occurred within 30 days of the index
procedure, irrespective of DAPT status. Moreover, DAPT interrup-
tions beyond 30 days were associated with a low risk of ST and no
increased risk of CD/TVMI.
Data from other newer generation stent platforms also show that
the greatest risk of ST is within the first 30 days and that the risk of ST
does not differ between patients on DAPT and off DAPT following
this time point.35 These data suggest that other factors such as pro-
cedural factors, implantation technique, and patient-related factors
impacting the risk for ST are especially important during the first
30 days post-procedure.36 –39 It is known that 4–7% of patients
undergoing PCI and stent placement will require non-cardiac
surgery in each year after treatment and thus it is often unavoidable
to interrupt DAPT before the 6–12 months post-procedure recom-
mended.40 Forpatients that interruptedDAPT in thecurrent analysis,
nearly all ST events (six of seven) occurred in patients who inter-
rupted DAPT between 0 and 1 month and onlyone patient that inter-
rupted DAPT after 1 and before 12 months had a ST.
While event numbers are small, interruption of DAPT after 1
month appeared to confer no additional risk for ST, compared with
no interruption of DAPT. However, interruption of DAPT during
the first month was associated with a greater risk of ST. The
log-rank P-value for the difference in ST rates between patients inter-
rupted between 1 and 12 months and patients interrupted within the
first month is ,0.0001, which would imply that the patients that
interrupted between 1–12 months has a lower risk of ST than
patients that interrupted within a month of R-ZES. These data do
not address patients who may be at a higher risk for ST regardless
of stent type but suggest that DAPT interruption after 1 month
may not confer increased risk for ST, CD, or MI for many patients
receiving a Resolute stent. While observational studies of the first
generation DES consistently showed a correlation between early
discontinuation of DAPT and higher rates of ST, it is not clear that
the same observations apply to new generation DES such as the
R-ZES, as evidenced by our observation that the rate of ST in patients
with a DAPT interruption after 1 month is quite low.
It is also important to consider the role of duration of interruption.
The thienopyridines, ticlopidine, andclopidogrel arepro-drugs meta-
bolized in the liver to active metabolites that are non-competitive
antagonists of the platelet adenosine diphosphate receptor, P2Y12.
Inhibition of platelet aggregation by these drugs is delayed until
24–48 h after administration, with maximal inhibition achieved
after 3–5 days. Studies have shown that it takes up to 14 days for
the platelet function to recover after DAPT withdrawal,32 which sup-
ports the relevance and importanceof assessingSTstatus for subjects
that interrupt for longer than 14 days given that a DAPT effect on
platelet function could still be active during shorter interruption
durations. Consistent with these data, the DAPT Study being con-
ducted in over 20 000 subjects uses a duration of DAPT longer
than 14 days to define compliance.41 In this analysis, no ST events
occurred in patients with longer than 14 day interruption in the
1–12-month interruption group. All six ST events in patients with
longer than14day interruptionoccurred in the1-month interruption
group.
When the reasons for DAPT interruption were investigated, we
noted no difference in the incidence of ST according to reason for
interruption although the small number of events precludes any
definitive conclusions. However a recently published observational
study of over 5000 patients looking at cessation of DAPT and
cardiac events after PCI observed a significantly greater risk for
major adverse cardiac events when patients disrupted their therapy
than when physicians chose to discontinue or interrupt DAPT.42
Prolonged use of antiplatelet drugs is a known risk for bleeding
events and there is evidence to suggest that for some patients,
DAPT extension beyond 3 months confers no additional benefit in
terms of reduction in ST events, but is associated with more major
bleeding events.43 Even mild-to-moderate bleeding events are asso-
ciated with a poorer long-term prognosis compared with those
patients without bleeding.44 These results (1.79% bleeding with no
DAPT interruption and 0.56% bleeding in DAPT interrupted
patients) are consistent with observations that there is an increased
risk for bleeding in the presence of DAPT.
In addition to the lack of safety benefit demonstrated with
extended use of DAPT, there is increasing evidence to show compar-
able safety outcomes in terms of ST and cardiac death with a shorter
DAPT duration than is currently recommended by guidelines. Ana-
lysis from multiple publications shows the greatest risk for ST and
cardiac death is observed when DAPT interruption occurs within
30 days after stent implantation.17,45– 48 These observations highlight
the need for randomized controlled trials to evaluate the risk vs.
benefit of very short (1 month) vs. longer durations of DAPT after
DES implantation.
Cardiac death/target-vessel myocardial
infarction
The clinical consequences of ST can be serious, with death and myo-
cardial infarction being the most severe. A pooled analysis of multi-
centre coronary stent trials and registries has shown that ST is a
rare but usually catastrophic event, frequently associated with a myo-
cardial infarction or death. The use of DAPT for a period longer than
12 months in patients who had received DESs was not significantly
more effective than aspirin monotherapy in reducing the rate of myo-
cardial infarction or death from cardiac causes in a previously rando-
mized study.22 Although not all cardiac deaths and myocardial
infarctions are ST-related, we analysed the occurrence of CD/
TVMI in patients with and without a longer than 14 day DAPT inter-
ruption toprovide amore inclusive assessmentof ST. Results support
the conclusion that the antiplatelet therapy discontinuation was not
necessarily followed by major cardiovascular events, at least in
patients with a prolonged DAPT interruption later than 1 month
after stenting.
There are several possible mechanisms explaining the relative
safety of the R-ZES. Pre-clinical studies of the BiolinxTM polymer
blend used on the R-ZES demonstrate that the hydrophilic surface
of this polymer coating does not induce an inflammatory response
and provides excellent biocompatibility.49 This observation was con-
firmed in a porcine coronary artery model showing minimal inflam-
mation following implantation of the R-ZES.50 Clinical studies have
also supported the safety of ZES. Forexample, some of these findings
might be explained by better neointimal coverage in the early post-
implant period compared with earlier generation DES.51,52 In
optical coherence tomography studies, most of the stent struts
were covered with neointima at 3 months after R-ZES implantation
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and the rates of malapposition (0.7+ 2.2%) and thrombus (1/18,
5.6%) were quite low,52 and exposure of stent struts and thrombi
was observed less frequently in patients undergoing PCI with ZES
than in those undergoing PCI with SES at 9-month follow-up.51
Although 1 yearof clinical follow-up may not be sufficient to assess
the very late outcomes, the data presented here are meaningful given
that the majority of the ST events occurs within the first year follow-
ing stent implantation. Moreover, the optimal duration of DAPT
might be different according to DES types. These data suggest for
R-ZES, DAPT use for the first month after stent placement is import-
ant but the necessity for continued DAPT beyond this time is unclear.
DES that can offer both safety and efficacy are desirable, especially for
those who may need to stop DAPT early after DES implantation.
Limitations
This is a post hoc analysis of pooled datasets that may not reflect the
higher ST risk likely to occur in routine clinical practice. Specifically,
the RESOLUTE-Japan and RESOLUTE-US trials enrolled subjects
likely to be at a lower risk for clinical events; however, the majority
(70%) of the patients included in this analysis was taken from the
RESOLUTE-International Registry (n ¼ 2349) and the RESOLUTE-
All Comers trial (n ¼ 1140) which enrolled a high proportion of high-
risk ‘real world’ patients.These results should notbe overinterpreted
in this observational database given that physicians may have appro-
priately selected those patients who could safely interrupt DAPT and
the small number of ST events that occurred after R-ZES implant-
ation. Additionally, most of the DAPT interruptions (often tempor-
ary and brief) occurred after 6 months making it difficult to sort
out the exact role of nature of the association between DAPT inter-
ruptions and adverse clinical events. The generalized application of
these results to the entire population demands careful attention
given that a larger sample size and a randomized trial might be
required to provide a definite answer regarding low frequency
events such as ST. The findings reported here apply only to R-ZES.
Because safety and efficacy differ according to the DES type, addition-
al analyses that determine the feasibility of short duration DAPT after
implantation of other DES are needed.
Conclusion
In a large pooled population of patients treated with an R-ZES, DAPT
interruptions between 1 and 12 months were associated with low
rates of ST and adverse cardiac outcomes. It would be inappropriate
to suggest any changes to the ESC or ACC/AHA/SCAI guidelines for
PCI post-stent implantation; however, the current analysis may
provide reassurance for clinicians and patients implanted with an
R-ZES who may need to interrupt or discontinue the medications
before the recommended duration for a variety of unplanned
reasons. Randomized clinical trials are needed to determine
whether early temporary or permanent interruption of DAPT is
truly safe.
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